

Cirrhosis in Over 16s: Assessment and Management Committee Meeting

**Date:** 6 February 2023

**Location:** Virtual Meeting via Zoom

**Minutes:** Final

<b>Committee members present:</b>	
Caroline Jones (Chair)	Present for all items
Vanessa Hebditch	Present for all items
Mathis Heydtmann	Present for all items
Kathryn Jack	Present for all items
Fatema Jessa	Present for all items
Alastair O'Brien	Present for all items
Emmanuel Wey	Present for all items

<b>NICE in attendance:</b>		
Keona Bennett	Administrator	Present for item 1
Chris Carmona	Technical Adviser	Present for all items
Lindsay Claxton	Technical Adviser, Health Economics	Present for all items
James Jagroo	Technical Analyst, NICE	Present for all items
Jon Littler	Project Manager	Present for all items
Karen Peplow	Technical Analyst	Present for all items
Clifford Middleton	Guideline Commissioning Manager, NICE	Present from item 3 onwards
Yuanyuan Zhang	Technical Analyst, Health Economics	Present for all items

<b>Apologies:</b>	
Nicola Cunliffe	Project Manager, NICE
Bethan Dorsett	Medical Editor, NICE
Andrew Fowell	Committee Member
Benjamin Gregory	Resource Impact Lead, NICE
Wesley Hubbard	Information Specialist, NICE
Imaad Rafiq	Committee Member
Magdalena Watras	Medicines Lead, NICE

## **1. Welcome, Introductions and Declaration of Interests**

The Chair welcomed the committee members and attendees to the second meeting on the Cirrhosis in over 16s: assessment and management update. The committee members and attendees introduced themselves.

The Chair outlined the objectives for the day.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Cirrhosis in over 16s assessment and management. The Chair then asked everyone to verbally declare any new interests that are not listed in the registry, but there were no new interests to declare.

## **2. Systematic reviews**

The Chair introduced Chris Carmona (CC), who gave a brief presentation to the committee on NICE's systemic review process, showing how we sift for data and assess it, and how it feeds into our evidence review process. The committee had no further questions on this item.

## **3. Review question 1 – non-selective beta-blockers (NSBBs) vs. endoscopic variceal band ligation (EVL) for preventing variceal bleeding**

The Chair introduced James Jagroo (JJ), who gave a presentation to the committee on the evidence supporting NSBB and EVL as treatments for variceal bleeding. He then took questions and comments from the committee.

CJ thanked JJ for his presentation and moved to the next item on the agenda.

## **4. Health economics presentation – NSBB vs. EVL**

The Chair introduced Lyndsey Claxton (LC) and Yuanyuan Zhang (YZ) to present the health economic evidence on NSBB and EVL treatments, covering the cost-effectiveness of both treatments and demonstrating how they had modelled this for various scenarios.

After taking questions from the committee, CJ thanked YZ and LC for their working in preparing and translating this evidence to an easy-to-understand format and moved to the next item on the agenda.

## **5. Committee discussion – non-selective beta-blockers (NSBBs) vs. endoscopic variceal band ligation (EVL) for preventing variceal bleeding**

Having been presented with all the clinical evidence, JJ returned to lead the committee on a discussion session where the outlines of potential recommendations were discussed, with the existing recommendation being used as a comparator.

CJ thanked the team for the data they'd presented this morning, and the committee for their contributions, and moved to the penultimate item on the agenda.

## **6. EIA discussion**

Karen Peploe (KP) led a discussion on the Equality Impact Assessment for this update, specifically around the issues discussed at this meeting relating to NSBBs and EVLs and whether or not new

considerations needed to be made in light of the discussion.

CJ thanks KP for this discussion and moved to the final item on the agenda.

**7. AOB, summary and next steps**

The Chair asked the committee if they had any other business, gave a summary, confirmed next steps, thanked everyone for their contributions, and the meeting concluded.